Products for Research Use Only
RegisterLogin

GSK3326595

CAT: 0804-HY-101563-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-101563-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5].
CAS Number
1616392-22-3
Product Name Alternative
EPZ015938
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Apoptosis; CDK; Histone Methyltransferase; MDM-2/p53; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/GSK3326595.html
Purity
99.83
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(C)N1CCC(NC2=NC=NC(C(NC[C@H](O)CN3CCC(C=CC=C4)=C4C3)=O)=C2)CC1
Molecular Formula
C24H32N6O3
Molecular Weight
452.55
Precautions
H315, H319, H335
References & Citations
[1]Li Z, et al. GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation [J]. Journal of Medical Virology, 2023, 95 (1) : e28158.|[2]Fedoriw A, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss [J]. Cancer cell, 2019, 36 (1) : 100-114. e25.|[3]Zhang Y, et al. PRMT5 inhibition induces pro‐inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice [J]. Journal of Cellular and Molecular Medicine, 2023, 27 (8) : 1056-1068.|[4]Che Y, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations [J]. Blood cancer journal, 2023, 13 (1) : 27.|[5]Luo Y, et al. Myelocytomatosis-protein arginine N-methyltransferase 5 Axis defines the tumorigenesis and immune response in hepatocellular carcinoma [J]. Hepatology, 2021, 74 (4) : 1932-1951.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK4; CDK6; PRMT5

Alternative Products

CatalogName
BA2257-50GSK3326595
S8664-5mgPemrametostat (GSK3326595)
TBI4028-5MGGSK3326595, Selective PRMT5 inhibitor

Popular Products